Vimarsana
Biggest News Aggregation in the World

Page 8 - Calculus Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Calculus Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Calculus Capital Today - Breaking & Trending Today

Roundup: AWS to launch data centres in UAE, Ibex obtains CE Mark for AI-powered breast cancer detection and more briefs - Vimarsana News

Roundup: AWS to launch data centres in UAE, Ibex obtains CE Mark for AI-powered breast cancer detection and more briefs

Also, X-on completes deployments of Surgery Connect cloud-telephony system in London and Greater Manchester.

Investegate |Calculus VCT Announcements | Calculus VCT: Correction to Dividend Record Date - Vimarsana News

Investegate |Calculus VCT Announcements | Calculus VCT: Correction to Dividend Record Date

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

Invizius Closes £5.3M Series A Financing - Vimarsana News

Invizius Closes £5.3M Series A Financing

Invizius Limited, a Motherwell, Scotland, UK-based biotechnology company developing treatments to suppress unwanted innate immune responses, closed Series A financing of £5.3m. The round was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Series A remains open to other investors until June 2021. The company intends to use the funds to complete a First-in-Man safety study in 2022 of its H-Guard ® Priming Solut...

Invizius Announces Successful Series A Financing to Develop Anti-Inflammatory Treatment for Haemodialysis - Vimarsana News

Invizius Announces Successful Series A Financing to Develop Anti-Inflammatory Treatment for Haemodialysis

Share this article Share this article MOTHERWELL, Scotland, May 6, 2021 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. Although already over-subscribed, the company's Series A remains open to ot...

Axol Bioscience and Censo Biotechnologies Announce Merger - Vimarsana News

Axol Bioscience and Censo Biotechnologies Announce Merger

Axol Bioscience and Censo Biotechnologies Announce Merger 03/17/2021 | 05:27am EDT Send by mail : Message : iPSC industry-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across shareholders, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of iPSC-derived cells, media, and characterization services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, today announced that the two companies ...